✦ LIBER ✦

A phase I trial of protracted oral fixed-dose temozolomide

✍ Scribed by Suzanne F. Jones; F. Anthony Greco; Victor G. Gian; Fernando T. Miranda; Eric L. Raefsky; John D. Hainsworth; Noel T. Willcutt; Aurelia F. Beschorner; Glyndon Kennerly; Howard A. Burris III

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 86 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21408

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of 4-demethoxydaunorubicin

Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses

✍ S. Kaplan; C. Sessa; Y. Willems; M. A. Pacciarini; V. Tamassia; F. Cavalli 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 454 KB

Twenty-four patients with a variety of solid tumors entered a Phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single oral dose of 10-60 mg/m 2 repeated every 3-4 weeks. Leukopenia was the dose-limiting toxicity. Other toxic effects included mild t

Phase I study of temozolomide and escala

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

✍ David N. Korones; Michal Benita-Weiss; Thomas E. Coyle; Laszlo Mechtler; Peter B 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

## Abstract ## BACKGROUND Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short‐lived. Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly

Phase 2 trial of temozolomide using prot

Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases

✍ Raffaele Addeo; Carmine De Rosa; Vincenzo Faiola; Luigi Leo; Gregorio Cennamo; L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

A Phase I trial of fixed dose rate gemci

A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma

✍ Brian I. Rini; Vivian Weinberg; Eric J. Small 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## Abstract ## BACKGROUND Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5‐fluorouracil (5‐FU). Fixed dose rate gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical effect. To determine the t

A phase I study of sequential administra

A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors

✍ Caio M. S. Rocha Lima; Carlo V. Catapano; Daniel Pacheco; Carol A. Sherman; Greg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND Based on preclinical findings and on the clinical antitumor efficacy of sequential paclitaxel/topotecan and topotecan/etoposide, the authors sought to define the maximum tolerated doses (MTDs) and dose‐limiting toxicities (DLTs) associated with a sequential combination of

Phase I trial of irinotecan plus temozol

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

✍ David A. Reardon; Jennifer A. Quinn; Jeremy N. Rich; Annick Desjardins; James Vr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB